Document Type

Article

Department

Haematology/Oncology; Pathology and Laboratory Medicine; Medical College Pakistan

Abstract

Eltrombopag has been used in ITP and found its use in AA armamentarium recently. We retrospectively analyzed 61 patients at a tertiary care center in Pakistan from January 2015 to January 2021. They included patients with severe AA who were refractory to at least one course of immunosuppressive therapy and persistent/chronic ITP who have received at least one previous treatment for ITP. Responses to Eltrombopag in our population were comparable to real-world experiences while tolerable hepatotoxicity and GI issues were notable. We found Eltrombopag to be a safe and efficacious agent for treating patients with ITP and AA.

Comments

Issue, and pagination are not provided by the author/publisher

Publication

Leukemia Research Reports

Share

COinS